Efmoroctocog alfa(Sobi Analytics) Due Diligence Report 2026

This Efmoroctocog alfa(Sobi Analytics) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Efmoroctocog alfa(Sobi Analytics) can convert its Fc fusion protein, Recombinant coagulation factor profile and F10 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Efmoroctocog alfa(Sobi Analytics) (query alias: efmoroctocog alfa)
Modality / target	Fc fusion protein, Recombinant coagulation factor; F10; F10 modulators, Coagulation factor VIII replacements
Highest global status	Approved
Originator	Sobi Analytics Ltd.
Active developers	Swedish Orphan Biovitrum AB, Sanofi KK, Biogen, Inc.

The MCP disease footprint includes Hemophilia A. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04728217	Phase 4	Completed	30	Health-related quality of life
NCT04690322	Phase 4	Withdrawn	Not disclosed	Changes in hemostatic potential
NCT04293523	Not Applicable	Active, not recruiting	427	Joint health: Target joint development

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A

Not Applicable; n=131; evaluation: Positive. Reported fields: Weekly factor consumption = 89.7 IU/kg ; Weekly factor consumption = 84.1 IU/kg

Immune Tolerance Induction With a Recombinant Factor <scp>VIII</scp> Fc in Haemophilia A: Data From a Chart Review Study

Not Applicable; n=17; evaluation: not stated. Reported fields: ITI success/partial success = 50.0 %

A Post Hoc Analysis of Previously Untreated Patients With Severe Hemophilia A Who Developed Inhibitors in PUPs A-LONG.

Phase 3; n=not disclosed; evaluation: not stated. Reported fields: Mean dose per infusion = 98.4 IU/kg

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Efmoroctocog alfa(Sobi Analytics) addresses Hemophilia A. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fc fusion protein, Recombinant coagulation factor—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2016-05-04	Biogen Spinning Off Hemophilia Business to Focus On Neurological Disorders	Not disclosed	Financial terms not disclosed
2014-09-19	Sobi expands Haemophilia development portfolio - elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO